+

WO2000023599A3 - Proteines humaines responsables de la degradation du reticulum endoplasmique (er) - Google Patents

Proteines humaines responsables de la degradation du reticulum endoplasmique (er) Download PDF

Info

Publication number
WO2000023599A3
WO2000023599A3 PCT/US1999/024563 US9924563W WO0023599A3 WO 2000023599 A3 WO2000023599 A3 WO 2000023599A3 US 9924563 W US9924563 W US 9924563W WO 0023599 A3 WO0023599 A3 WO 0023599A3
Authority
WO
WIPO (PCT)
Prior art keywords
cftr
human proteins
degradation
endoplasmic reticulum
proteins involved
Prior art date
Application number
PCT/US1999/024563
Other languages
English (en)
Other versions
WO2000023599A2 (fr
Inventor
Vincent Chau
Original Assignee
Leukosite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukosite Inc filed Critical Leukosite Inc
Priority to EP99955088A priority Critical patent/EP1123385A2/fr
Priority to JP2000577306A priority patent/JP2002527111A/ja
Priority to CA002348156A priority patent/CA2348156A1/fr
Priority to AU11272/00A priority patent/AU1127200A/en
Publication of WO2000023599A2 publication Critical patent/WO2000023599A2/fr
Publication of WO2000023599A3 publication Critical patent/WO2000023599A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne la dégradation de protéines par la voie ubiquitine-protéasome. Plus particulièrement, l'invention concerne la dégradation de protéines dans l'ER, y compris le régulateur de perméabilité transmembranaire de la fibrose kystique (CFTR) par la voie ubiquitine-protéasome. L'invention concerne également des méthodes et compositions d'inhibition de cette dégradation et d'activation de la maturation de ΔF508 dans un CFTR fonctionnel, ainsi que de compréhension du rôle de la perte de fonction du CFTR dans la fibrose kystique. L'invention concerne enfin la découverte de protéines responsables du transfert d'ubiquitine dans ΔF508, CFTR et α1-AT.
PCT/US1999/024563 1998-10-21 1999-10-21 Proteines humaines responsables de la degradation du reticulum endoplasmique (er) WO2000023599A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99955088A EP1123385A2 (fr) 1998-10-21 1999-10-21 Proteines humaines responsables de la degradation du reticulum endoplasmique (er)
JP2000577306A JP2002527111A (ja) 1998-10-21 1999-10-21 小胞体タンパク質分解に関与するヒトタンパク質
CA002348156A CA2348156A1 (fr) 1998-10-21 1999-10-21 Proteines humaines responsables de la degradation du reticulum endoplasmique (er)
AU11272/00A AU1127200A (en) 1998-10-21 1999-10-21 Human proteins responsible for er degradation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10506498P 1998-10-21 1998-10-21
US60/105,064 1998-10-21

Publications (2)

Publication Number Publication Date
WO2000023599A2 WO2000023599A2 (fr) 2000-04-27
WO2000023599A3 true WO2000023599A3 (fr) 2000-09-14

Family

ID=22303856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024563 WO2000023599A2 (fr) 1998-10-21 1999-10-21 Proteines humaines responsables de la degradation du reticulum endoplasmique (er)

Country Status (5)

Country Link
EP (1) EP1123385A2 (fr)
JP (1) JP2002527111A (fr)
AU (1) AU1127200A (fr)
CA (1) CA2348156A1 (fr)
WO (1) WO2000023599A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040486A2 (fr) * 1997-03-14 1998-09-17 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
US5817494A (en) * 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
WO1999015659A2 (fr) * 1997-09-23 1999-04-01 Incyte Pharmaceuticals, Inc. Enzymes de conjugaison de l'ubiquitine humaine
WO1999050421A1 (fr) * 1998-03-27 1999-10-07 University Of Leeds Enzyme conjuguant l'ubiquitine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040486A2 (fr) * 1997-03-14 1998-09-17 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
US5817494A (en) * 1997-05-21 1998-10-06 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
US5922318A (en) * 1997-05-21 1999-07-13 Incyte Pharmaceuticals, Inc. Ubiquitin conjugation proteins
WO1999015659A2 (fr) * 1997-09-23 1999-04-01 Incyte Pharmaceuticals, Inc. Enzymes de conjugaison de l'ubiquitine humaine
WO1999050421A1 (fr) * 1998-03-27 1999-10-07 University Of Leeds Enzyme conjuguant l'ubiquitine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIECHANOVER A ET AL: "THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM: INVOLVEMENT OF MOLECULARCHAPERONES, DEGRADATION OF ONCOPROTEINS, AND ACTIVATION OF TRANSCRIPTIONAL REGULATORS", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY,US,NEW YORK, NY, vol. 60, 1 January 1995 (1995-01-01), pages 491 - 501, XP002069094 *
CIECHANOVER A: "THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 79, 7 October 1994 (1994-10-07), pages 13 - 21, XP002069095, ISSN: 0092-8674 *
COOK, J.W. ET AL.: "Crystal structure of a class I ubiquitin conjugating enzyme (Ubc7) from Saccharomyces cerevisiae at 2.9 Angstrom resolution", BIOCHEMISTRY, no. 36, June 1997 (1997-06-01), pages 1621 - 1627, XP002139695 *

Also Published As

Publication number Publication date
JP2002527111A (ja) 2002-08-27
CA2348156A1 (fr) 2000-04-27
EP1123385A2 (fr) 2001-08-16
AU1127200A (en) 2000-05-08
WO2000023599A2 (fr) 2000-04-27

Similar Documents

Publication Publication Date Title
AU1730600A (en) Tobacco flavoring components of enhanced aromatic content and method of providing same
AU3932999A (en) Pyrazoline derivatives, their preparation and application as medicaments
AU7363600A (en) Breath freshening comestible product
AU2001261047A1 (en) Secured content delivery system and method
AU6666898A (en) Internet switch box, system and method for internet telephony
AU2002227280A1 (en) Protein modification and maintenance molecules
AU2350700A (en) Effervescence components
AU4871797A (en) Magnesium (-)hydroxycitrate, preparation process, uses and compositions, in particular pharmaceutical compositions, containing it
AU7820298A (en) Dermatological healing kit, components therefor, and process for making
AU2001253154A1 (en) Wavelength monitor/locker using an etalon and associated methods
AU4873197A (en) Novel (alpha-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof
AU2936099A (en) Internet protocol switch and method
EP1085774A3 (fr) Architecture de mobilité en H.323 pour mobilité d'utilisateurs de terminaux et services
AU2001295483A1 (en) Solid peptide preparations for inhalation, and the production thereof
AU6499798A (en) Stable, solid preparation comprising vitamin D3 and tricalcium phosphate
AU2001270271A1 (en) Protein modification and maintenance molecules
AU2001280035A1 (en) Intracellular delivery system for protein phosphatases and other polypeptides
WO2000023599A3 (fr) Proteines humaines responsables de la degradation du reticulum endoplasmique (er)
AU2001294291A1 (en) Immediate lottery processing system via internet and method therefor
AU2362701A (en) Fragrance or flavor formulation
AU6423600A (en) The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof
AU3983899A (en) Human promonocyte associated protein: prmnc
WO2002077233A8 (fr) Methodes associees a 38650, 28472, 5495, 65507, 81588 et 14354, compositions de proteines humaines correspondantes et leurs utilisations
AU1931097A (en) Antimicrobial composition, particularly for antisepsis and/or disinfection
AU2001259862A1 (en) Method and system for online custom footwear preparation

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11272

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2348156

Country of ref document: CA

Ref country code: CA

Ref document number: 2348156

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 577306

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999955088

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999955088

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999955088

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载